GABRIEL NILES: Open Payments
NPI 1285611699 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 31 payments from 15 companies in 2025. Trend: 2023 $503 · 2024 $791 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $161 |
| Lilly USA, LLC | 4 | $97 |
| ABBVIE INC. | 3 | $78 |
| Novo Nordisk Inc | 3 | $67 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Tandem Diabetes Care, Inc. | 1 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Boston Scientific Corporation | 1 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
Products named: Kerendia, MOUNJARO, REZDIFFRA, t:slim X2 Insulin Pump with Control-IQ, GEMTESA, WaveWriter Alpha Prime 16, GVOKE HYPOPEN, VOWST.
Industry payments across CA — which companies pay providers there.
